Reboxetine use in the treatment of attention-deficit/hyperactivity disorder

J Child Adolesc Psychopharmacol. 2006 Dec;16(6):803-4. doi: 10.1089/cap.2006.16.803.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Adolescent
  • Antidepressive Agents / adverse effects
  • Antidepressive Agents / therapeutic use*
  • Antidepressive Agents, Tricyclic / therapeutic use
  • Attention Deficit Disorder with Hyperactivity / drug therapy*
  • Attention Deficit Disorder with Hyperactivity / psychology
  • Central Nervous System Stimulants / adverse effects
  • Central Nervous System Stimulants / therapeutic use
  • Child
  • Female
  • Humans
  • Imipramine / therapeutic use
  • Male
  • Methylphenidate / adverse effects
  • Methylphenidate / therapeutic use
  • Morpholines / adverse effects
  • Morpholines / therapeutic use*
  • Reboxetine

Substances

  • Antidepressive Agents
  • Antidepressive Agents, Tricyclic
  • Central Nervous System Stimulants
  • Morpholines
  • Methylphenidate
  • Reboxetine
  • Imipramine